Article
Oncology
Monica Sanchez-Guixe, Cinta Hierro, Jose Jimenez, Cristina Viaplana, Guillermo Villacampa, Erika Monelli, Fara Braso-Maristany, Zighereda Ogbah, Mireia Pares, Marta Guzman, Judit Grueso, Olga Rodriguez, Mafalda Oliveira, Analia Azaro, Elena Garralda, Josep Tabernero, Oriol Casanovas, Maurizio Scaltriti, Aleix Prat, Rodrigo Dienstmann, Paolo Nuciforo, Cristina Saura, Mariona Graupera, Ana Vivancos, Jordi Rodon, Violeta Serra
Summary: FGFR1 amplification is common in breast cancer and is associated with resistance to endocrine therapy and CDK4/6 inhibitors. High levels of FGFR1-4 mRNA expression are predictive of response to FGFRis, while MTKIs show higher response rates. These findings suggest that tailored therapy based on high mRNA levels may be effective in treating breast cancer patients.
CLINICAL CANCER RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Matteo Repetto, Edoardo Crimini, Federica Giugliano, Stefania Morganti, Carmen Belli, Giuseppe Curigliano
Summary: This study presents clinical data on selective FGFR/FGF pathway inhibitors, describing resistance mutations and mechanisms. FGFR/FGF pathway inhibitors are classified based on the signaling mechanism and preferred FGFR binding mode.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2021)
Article
Oncology
Mikkel G. Terp, Kirstine Jacobsen, Miguel Angel Molina, Niki Karachaliou, Hans C. Beck, Jordi Bertran-Alamillo, Ana Gimenez-Capitan, Andres F. Cardona, Rafael Rosell, Henrik J. Ditzel
Summary: Resistance to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC patients is often associated with increased FGFR1 expression and Akt activation, leading to the development of targeted therapy strategies for overcoming resistance. Combination therapy targeting both FGFR and Akt has shown superior growth inhibition of resistant cells in vitro and in vivo, providing a promising rationale for future clinical trials in NSCLC patients.
NPJ PRECISION ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
David Wai Meng Tai, Thi Bich Uyen Le, Aldo Prawira, Rebecca Zhi Wen Ho, Hung Huynh
Summary: For HCC patients with high FGFR2/3 or FGF19/FGFR4 expressing tumors, combination therapy with infigratinib and FGF401 showed favorable initial treatment response but also delayed onset of resistance and inhibited metastasis, supporting its evaluation in clinical trials.
HEPATOLOGY INTERNATIONAL
(2021)
Review
Oncology
Patrick C. Lee, Andrew Hendifar, Arsen Osipov, May Cho, Daneng Li, Jun Gong
Summary: Cholangiocarcinoma is a cancer arising from the bile ducts and chemotherapy has been the standard treatment for metastatic cases. However, recent clinical trials have shown that FGFR inhibitors are a promising new treatment for advanced CCA with specific genetic alterations. This review provides an overview of genetic features, FGFR pathway biology, important clinical trials, and future opportunities and challenges for FGFR inhibitors in treating CCA.
Article
Multidisciplinary Sciences
Evan Flietner, Zhi Wen, Adhithi Rajagopalan, Oisun Jung, Lyndsay Watkins, Joshua Wiesner, Xiaona You, Yun Zhou, Yuqian Sun, Brock Kingstad-Bakke, Natalie S. Callander, Alan Rapraeger, M. Suresh, Fotis Asimakopoulos, Jing Zhang
Summary: This study found that ponatinib has moderate killing activity against multiple myeloma (MM) and strong synergism with trametinib (Tra) in vitro. However, ponatinib inhibits T cell function, which may partially counteract its synergistic killing effect with Tra in vivo.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Otto Metzger Filho, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell'Orto, Leila Russo, Tari A. King, Kornelia Polyak, Franziska Michor, Eric P. Winer, Ian E. Krop
Summary: Intratumor heterogeneity, particularly the fraction of ERBB2 nonamplified cancer cells, is strongly correlated with resistance to HER2-targeted therapies and could potentially aid in optimizing treatment selection for HER2-positive breast cancer patients.
Article
Agricultural Engineering
Pavallekoodi Gnasekaran, Zuraida Abdul Rahman, Bee Lynn Chew, Jasim Uddain, Vanitha Mariappan, Suganthi Appalasamy, Sreeramanan Subramaniam
Summary: This study analyzed the effects of different light qualities on the chloroplast ultrastructure and adventitious bud anatomy of Zingiber officinale var. rubrum Theilade, demonstrating the impact of LED spectral quality on plant growth and genetic characteristics. The results showed that LED lighting promoted plant growth, but also affected chloroplast ultrastructure by increasing starch accumulation.
INDUSTRIAL CROPS AND PRODUCTS
(2022)
Article
Acoustics
Renata Sisto, Daniele Belardinelli, Arturo Moleti
Summary: This paper discusses the role of 2-D/3-D cochlear fluid hydrodynamics in the generation of large non-linear dynamics range of the basilar membrane and pressure response, in the decoupling between cochlear gain and tuning, and in the dynamic stabilization of the high-gain BM response in the peak region. The study shows that the hydrodynamic phenomena yield stable high-gain response in the peak region and a smooth transition among models with different effectiveness of the active mechanism.
JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
(2021)
Review
Pharmacology & Pharmacy
Jasmine Davda, Kellie Reynolds, John D. Davis, Patrick F. Smith
Summary: The most important lesson learned from the COVID-19 pandemic is the importance of preparedness. Enhancing surveillance systems, drug discovery, clinical pharmacology, translational medicine, and pharmacometrics tools are key components in rapidly identifying and developing interventions. Tailoring deployment strategies based on epidemiology and utilizing an interdisciplinary framework could optimize decision-making and treatment outcomes in pandemic responses.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Nutrition & Dietetics
Adi Anafy, Hadar Moran-Lev, Niva Shapira, Meital Priel, Asaf Oren, Laurence Mangel, Dror Mandel, Ronit Lubetzky
Summary: This study found that cow's milk protein-based, soy protein-based, and lactose-free infant formulas have similar glycemic index. However, the soy protein-based formula produced a significantly higher increase in postprandial glucose levels compared to the other formulas.
Article
Psychology, Clinical
Aileen Echiverri-Cohen, Lucas Spierer, Marcelina Perez, Melissa Kulon, Montana Daunbi Ellis, Michelle Craske
Summary: The study found that response inhibition training can improve inhibition on untrained tasks, reduce PTSD symptoms, and have better outcomes compared to a waitlist group post-training. However, there was evidence of reduced inhibition on a modified response inhibition task from pre- to post-training.
BEHAVIOUR RESEARCH AND THERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Audrys G. Pauza, Pratik Thakkar, Tatjana Tasic, Igor Felippe, Paul Bishop, Michael P. Greenwood, Kristina Rysevaite-Kyguoliene, Julia Ast, Johannes Broichhagen, David J. Hodson, Helio C. Salgado, Dainius H. Pauza, Nina Japundzic-Zigon, Julian F. R. Paton, David Murphy
Summary: The study found that GLP1R is expressed in the carotid bodies of rats and humans, and its decreased expression is associated with sympathetic hyperactivity. Targeted administration of GLP1R agonist can reduce the baseline discharge rate of the carotid body and attenuate blood pressure and sympathetic responses induced by chemoreflex. Importantly, GLP1R activation can eliminate hyperglycemia-induced peripheral chemoreflex sensitization and associated sympathetic overactivity.
CIRCULATION RESEARCH
(2022)
Article
Medicine, General & Internal
Luke J. Laffin, David Rodman, James M. Luther, Anand Vaidya, Matthew R. Weir, Natasa Rajicic, B. T. Slingsby, Steven E. Nissen, Target HTN Investigators
Summary: Excess aldosterone production is a contributor to hypertension, and therapies that reduce aldosterone synthesis may lower blood pressure. This study compares the safety and efficacy of an aldosterone synthase inhibitor, lorundrostat, with placebo, and identifies dose-dependent outcomes to inform future trials.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Cardiac & Cardiovascular Systems
Adolfo Fontenla, Juan Tamargo, Ricardo Salgado, Maria Lopez-Gil, Elena Mejia, Roberto Matia, Jorge Toquero, Isabel Montilla, Ez-Alddin Rajjoub, Francisco-Javier Garcia-Fernandez, Angel Miracle, Juan-Ramon Rey, Hector Bueno
Summary: This study suggests that ivabradine may reduce heart rate in patients with atrial fibrillation by inhibiting the funny current in the atrioventricular node. Compared with digoxin, ivabradine has a lower efficacy in rate reduction, but is better tolerated and has a similar rate of serious adverse events.
Editorial Material
Oncology
Maria Antonietta Cerone, Tara C. Mills, Rowena Sharpe, David McBride, Moira MacDonald, Suzanne MacMahon, Hood Mugalaasi, Pauline Rehal, Alessandro Rettino, Helen Roberts, Mark Ross, Donald Edward White, John Peden, Janette N. Rawlings, Stephan N. Ho, Simon Hollingsworth, Sanjay Popat, Gary Middleton, Peter Johnson, Charles Swanton
Summary: Genomic screening is widely used for cancer patient treatment guidance, but its timely delivery in clinical practice is hindered by multiple factors. This article shares insights from the CRUK-funded Stratified Medicine Programme for advanced NSCLC patients, providing valuable learnings for future research planning.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Federica Papaccio, Blanca Garcia-Mico, Francisco Gimeno-Valiente, Manuel Cabeza-Segura, Valentina Gambardella, Maria Fernanda Gutierrez-Bravo, Clara Alfaro-Cervello, Carolina Martinez-Ciarpaglini, Pilar Rentero-Garrido, Sheila Zuniga-Trejos, Juan Antonio Carbonell-Asins, Tania Fleitas, Susana Rosello, Marisol Huerta, Manuel M. Sanchez M. del Pino, Luis Sabater, Desamparados Roda, Noelia Tarazona, Andres Cervantes, Josefa Castillo
Summary: This study generated patient-derived organoids (PDOs) from advanced colorectal cancer (CRC) patients and integrated drug response with multi-omics characterization. By using SWATH-MS and RNA-seq analysis, they identified baseline proteins and gene expression profiles that could predict treatment response and aid in the development of personalized cancer therapeutics.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
David K. Lau, Maria Aresu, Timothy Planche, Amina Tran, Retchel Lazaro-Alcausi, Julie Duncan, Shannon Kidd, Susan Cromarty, Ruwaida Begum, Isma Rana, Su Li, Ali Abdulnabi Mohamed, Irene Monahan, David J. Clark, Nicholas Eckersley, Henry M. Staines, Elisabetta Groppelli, Sanjeev Krishna, Martin Mayora-Neto, Nigel Temperton, Charlotte Fribbens, David Watkins, Naureen Starling, Ian Chau, David Cunningham, Sheela Rao
Summary: The study evaluated the prevalence of neutralizing antibodies in 152 gastrointestinal cancer patients receiving chemotherapy after SARS-CoV-2 vaccination, finding that despite the immunosuppressive effects of chemotherapy, two doses of vaccines can still induce a protective immune response in patients undergoing treatment.
Review
Oncology
Martin Reck, Sanjay Popat, Christian Grohe, Jesus Corral, Silvia Novello, Maya Gottfried, Wolfgang Brueckl, Dejan Radonjic, Rolf Kaiser, John Heymach
Summary: The use of immune checkpoint inhibitors (ICIs) as first-line treatment for advanced non-small cell lung cancer (NSCLC) has been a major breakthrough. However, there is a need for effective second-line treatment options, prompting research into the combination of anti-angiogenic agents with immunotherapy. Ongoing clinical trials are evaluating the efficacy of these combinations.
Article
Multidisciplinary Sciences
Kevin Ng, Jesse Boumelha, Katey S. S. Enfield, Jorge L. Almagro, Hongui M. Cha, Oriol Pich, Takahiro Karasaki, David Moore, Roberto Salgado, Monica Sivakumar, George Young, Miriam L. Molina-Arcas, Sophie de Carne Trecesson, Panayiotis Anastasiou, Annika C. Fendler, Lewis Au, Scott T. C. Shepherd, Carlos Martinez-Ruiz, Clare Puttick, James R. M. Black, Thomas B. K. Watkins, Hyemin Kim, Seohee Shim, Nikhil Faulkner, Jan A. Attig, Selvaraju Veeriah, Neil J. Magno, Sophia T. Ward, Alexander Frankell, Maise Al Bakir, Emilia Lim, Mark Hill, Gareth Wilson, Daniel Cook, Nicolai Birkbak, Axel Behrens, Nadia Yousaf, Sanjay Popat, Allan Hackshaw, TRACERx Consortium, CAPTURE Consortium, Crispin T. Hiley, Kevin Litchfield, Nicholas McGranahan, Mariam Jamal-Hanjani, James Larkin, Se-Hoon Lee, Samra Turajlic, Charles Swanton, Julian Downward, George Kassiotis
Summary: This study reveals that lung adenocarcinomas in both humans and mice elicit local germinal center responses and tumour-binding antibodies, with endogenous retrovirus (ERV) envelope glycoproteins as the dominant anti-tumour antibody target. ERV-targeting B cell responses are enhanced by immune checkpoint blockade (ICB) and targeted inhibition of KRAS(G12C). ERV-reactive antibodies have anti-tumour activity and improve survival in a mouse model, and ERV expression predicts the response to ICB in human lung adenocarcinoma. Furthermore, the study demonstrates that effective immunotherapy in the mouse model requires CXCL13-dependent tertiary lymphoid structure (TLS) formation, and therapeutic CXCL13 treatment enhances anti-tumour immunity and synergizes with ICB. These findings provide a potential mechanistic basis for the association between TLS and immunotherapy response.
Letter
Oncology
Dima El-Sharkawi, Amit Sud, Catherine Prodger, Jahanzaib Khwaja, Rohan Shotton, Brian Hanley, Victoria Peacock, Ying Ying Peng, Anita Arasaretnam, Sarkhara Sharma, Frances Aldridge, Bhupinder Sharma, Andrew Wotherspoon, Betty Cheung, Corinne De Lord, Rosalynd Johnston, Shireen Kassam, Ruth Pettengel, Kim Linton, Paul Greaves, Lucy Cook, Kikkeri N. Naresh, Kate Cwynarski, Toby A. Eyre, Ian Chau, David Cunningham, Sunil Iyengar
BLOOD CANCER JOURNAL
(2023)
Article
Microbiology
James L. Alexander, Joram M. Posma, Alasdair Scott, Liam Poynter, Sam E. Mason, M. Luisa Doria, Lili Herendi, Lauren Roberts, Julie A. K. McDonald, Simon Cameron, David J. Hughes, Vaclav Liska, Simona Susova, Pavel Soucek, Verena Horneffer-van Der Sluis, Maria Gomez-Romero, Matthew R. Lewis, Lesley Hoyles, Andrew Woolston, David Cunningham, Ara Darzi, Marco Gerlinger, Robert Goldin, Zoltan Takats, Julian R. Marchesi, Julian Teare, James Kinross
Summary: This study investigates the association between gut microbiota, metabolome, and colorectal cancer (CRC). The authors identify specific microbiota clusters, such as cluster 7 containing Fusobacterium nucleatum and Granulicatella adiacens, that are strongly associated with CRC and can predict favorable disease-free survival. They also find that cluster 1 containing Faecalibacterium prausnitzii and Ruminococcus gnavus is negatively associated with cancer and predicts worse disease-free survival. In addition, certain metabolic clusters show associations with CRC, such as Met 1 composed of fatty acids, ceramides, and lysophospholipids, which is negatively associated with CRC, and Met 2 composed of phosphatidylcholine species, nucleosides, and amino acids, which is strongly associated with CRC.
Meeting Abstract
Oncology
J. Mencel, F. Turkes, L. Barber, B. Challoner, M. Buzzetti, A. Tran, H. Chen, N. McCafferty, A. Woolston, R. Crux, I. Rana, J. Thomas, V. Borja, R. Begum, E. Johnston, N. Fotiadis, M. Terlizzo, S. Rao, I. Chau, D. Cunningham, M. Gerlinger, N. Starling
ANNALS OF ONCOLOGY
(2023)
Meeting Abstract
Oncology
M. Kloft, W. Allum, D. Cunningham, R. Langley, M. Nankivell, D. Magee, H. Grabsch
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Nalinie Joharatnam-Hogan, Duaa Hatem, Fay H. Cafferty, Giovanna Petrucci, David A. Cameron, Alistair Ring, Howard G. Kynaston, Duncan C. Gilbert, Richard H. Wilson, Richard A. Hubner, Daniel E. B. Swinson, Siobhan Cleary, Alex Robbins, Mairead MacKenzie, Martin W. G. Scott-Brown, Sharmila Sothi, Lesley K. Dawson, Lisa M. Capaldi, Mark Churn, David Cunningham, Vincent Khoo, Anne C. Armstrong, Nicola L. Ainsworth, Gail Horan, Duncan A. Wheatley, Russell Mullen, Fiona J. Lofts, Axel Walther, Rebecca A. Herbertson, John D. Eaton, Ann O'Callaghan, Andrew Eichholz, Mohammed M. Kagzi, Daniel M. Patterson, Krishna Narahari, Jennifer Bradbury, Zuzana Stokes, Azhar J. Rizvi, Georgina A. Walker, Victoria L. Kunene, Narayanan Srihari, Aleksandra Gentry-Maharaj, Angela Meade, Carlo Patrono, Bianca Rocca, Ruth E. Langley
Summary: Ongoing clinical trials are assessing whether aspirin can prevent or delay metastases in cancer patients. It was found that platelet activation levels in post-surgery cancer patients are associated with tumor type, recent treatment, and aspirin use. The study suggests that aspirin, especially at a dose of 100 mg, may help inhibit platelet activation and potentially prevent cancer metastasis.
BRITISH JOURNAL OF CANCER
(2023)
Editorial Material
Medicine, General & Internal
Hazel O'Sullivan, Sanjay Popat
Meeting Abstract
Oncology
Susanna Slater, Annette Bryant, Maria Aresu, Ruwaida Begum, Hsiang-Chi Chen, Clare Peckitt, Retchel Lazaro-Alcausi, Paul Carter, Gayathri Anandappa, Shelize Khakoo, Graham Branagan, Nicol George, Muti Abulafi, Sarah Duff, Nicholas West, Leslie Bucheit, Thereasa A. Rich, Ian Chau, Naureen Starling, David Cunningham
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Avani Athauda, Tatiany Silveira, Thomas Lund, Katharina von Loga, Benjamin Challoner, Isma Rana, Janet Thomas, Naureen Starling, Ian Chau, Sheela Rao, David J. Watkins, David Cunningham, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Meeting Abstract
Oncology
Anderley Gordon, Benjamin Challoner, Avani Athauda, Andrew Woolston, Sonia Mansukhani, Matt Dunstan, Nikoletta Petrou, Komel Khabra, Retchel Lazaro-Alcausi, Richard Crux, Victoria Borja, Ruwaida Begum, Isma Rana, Sheela Rao, Sacheen Kumar, David Cunningham, Ian Chau, Naureen Starling, M. Asif Chaudry, Marco Gerlinger
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Domingo Antonio Sanchez Martinez, Aliica Quilez-Cutillas, Pablo Jimenez-Labaig, Andrea Sesma, Noelia Tarazona, Vilma Pacheco-Barcia, Berta Obispo, David Paez, Teresa Quintanar, Manuel Sanchez-Canovas, Ana Fernandez Montes, Enriqueta Felip, Alvaro Rodriguez-Lescure, Elena Elez
Summary: This study evaluated the professional standing of young medical oncologists in Spain, finding that many participants chose subspecialties based on job opportunities rather than personal interest. Concerns about job stability and a significant interest in working abroad were observed. Temporary contracts may have affected their career development.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2023)